Skip to main
ORGO

Organogenesis Holdings (ORGO) Stock Forecast & Price Target

Organogenesis Holdings (ORGO) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Organogenesis Holdings is a leader in the growing regenerative medicine market, with its strong portfolio of innovative products in the advanced wound care and sports medicine categories. While the company's financial performance has faced some turbulence due to changes in reimbursement structures, we believe that Organogenesis is well-positioned for long-term success, with a large and underpenetrated market opportunity. We see potential for competitive share gains, continued growth in the advanced wound care market, and success in clinical development and milestones. With a diverse portfolio and potential for market consolidation, we have a positive outlook for Organogenesis's stock.

Bears say

Organogenesis Holdings is facing multiple challenges, including lower-than-expected growth for its key product PuraPly, potential pricing pressure from Medicare Part B, increased competition from competitors, and potential issues with Medicare Administrative Contractors. Additionally, there is uncertainty regarding the uptake of new products and potential negative outcomes from clinical data. These factors could lead to lower-than-expected revenue and earnings, putting pressure on the company's stock price.

Organogenesis Holdings (ORGO) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Organogenesis Holdings (ORGO) Forecast

Analysts have given Organogenesis Holdings (ORGO) a Buy based on their latest research and market trends.

According to 2 analysts, Organogenesis Holdings (ORGO) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Organogenesis Holdings (ORGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.